Covidien has announced CE mark approval for its EverFlex Self-Expanding Peripheral Stent with Entrust Delivery System.
On 5 February 2013, IDEV Technologies announced the publication of positive clinical outcomes for the Supera peripheral stent system in the Journal of American College of Cardiology (JACC) Cardiovascular Interventions. The publication, “Treatment of Complex Atherosclerotic Popliteal Artery Disease with a New Self-Expanding Interwoven Nitinol Stent: 12-Month Results of the Leipzig Supera Popliteal Registry,” was authored by Dierk Scheinert and colleagues from Park Krankenhaus Hospital in Leipzig, Germany.
Daiichi Sankyo Europe announced the enrolment of the first patient into the PREFER in VTE (Prevention of thromboembolic events – European registry in venous thromboembolism) study on 6 February 2013. PREFER in VTE is the first patient registry to gather comprehensive data on the quality of life and treatment satisfaction of patients with venous thromboembolism (VTE). It will also provide detailed insights into the process of patient management in the acute treatment phase, as well as in the prevention of repeat thromboembolic events. In addition, the PREFER in VTE registry will investigate the economic burden of venous thromboembolism treatment.
Medtronic has announced completion of enrolment in IN.PACT SFA II, the US arm of its clinical study for the IN.PACT Admiral drug-eluting balloon as a treatment for peripheral arterial disease in the superficial femoral and proximal popliteal arteries.
The results of PEARL (Registry of AngioJet use in the peripheral vascular system), a phase II multicentre registry, led by Robert Lookstein, chief of interventional radiology, Mount Sinai Medical Center, New York, USA, have suggested that rheolytic pharmacomechanical thrombectomy using combination therapy is fast and effective and can reduce treatment time for deep vein thrombosis from more than two days to less than 24 hours according to data presented at the Annual International Symposium on Endovascular Therapy (ISET).
Volcano announced on 1 February 2013 it has a new interactive educational tool to facilitate learning about IVUS-guided interventional procedures with its new Visions PV .035 Digital IVUS catheter. The new Aortic IVUS App for iPad, available on the Apple App Store, provides case examples with interactive education on the procedural workflow and image interpretation, and is intended for healthcare professionals involved in endovascular aortic procedures.
Treating abdominal aortic aneurysm patients in an outpatient setting is feasible, with 0% mortality in a series conducted in Switzerland, according to data presented at the Controversies & Updates in Vascular Surgery symposium (17–19 January 2013) in Paris, France. Mario Lachat, University Hospital Zurich, Switzerland, told delegates that this type of procedure saves hospital costs and can be used in up to 40% of EVAR patients.
AngioScore has announced the launch of its new 100mm length AngioSculpt PTA Scoring Balloon Catheters for the treatment of peripheral arterial disease (PAD) below the knee (BTK).
Gore has introduced the Gore DrySeal sheath with hydrophilic coating in Europe. The new Gore DrySeal Sheath allows for easier insertion into and removal from blood vessels during endovascular repair procedures. The device is designed to increase sheath lubricity with an advantage of minimizing particulation of the hydrophilic coating.
Covidien announced on 23 January 2013 CE mark approval for its EverFlex self-expanding peripheral stent with Entrust delivery system. The advanced stent delivery system, specifically engineered for optimal control, is designed to allow physicians to consistently place stents in the desired location with accuracy and ease. The product will be rolled out in Western Europe next month.
Cardiovascular Systems announced on 23 January 2013 CONFIRM study series data presented at the 2013 International Symposium on Endovascular Therapy (ISET). Results show that CSI’s minimally invasive orbital atherectomy system is an effective treatment for peripheral arterial disease.
Spectranetics announced on 24 January 2013 final results from the PATENT (Photo-ablation using the Turbo-Booster and Excimer laser for in-stent restenosis treatment) study evaluating the safety and efficacy of the Spectranetics peripheral laser atherectomy catheters for the treatment of in-stent restenosis in the femoropopliteal artery in the leg.
Medtronic has announced the CE mark and international launch of its Complete SE (self-expanding) vascular stent for use in the lower extremities – specifically, the superficial femoral arteries and proximal popliteal arteries. In the United States, the Complete SE stent is approved by the FDA only for use in the iliac arteries.
Endologix announced on 24 January 2013 achievement of the CE mark of the Nellix EndoVascular Aneurysm Sealing System for the treatment of patients with abdominal aortic aneurysms. Nellix is the first available endovascular aneurysm sealing (EVAS) system. EVAS with Nellix is an advanced treatment strategy designed to simplify endovascular abdominal aortic aneurysm procedures, treat a broad range of patients, and provide enhanced clinical outcomes. The Nellix system is not approved in the United States for either investigational use or commercial sale.
Los pacientes con las arterias de las piernas bloqueadas tienen menos probabilidades de sufrir complicaciones tras un procedimiento para abrir sus arterias si dejan de fumar y toman aspirina y estatinas para reducir el colesterol, indica un estudio reciente.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos